MyoCon! September 24–27, 2026.If you’ve been following developments in myositis research, you’ve probably heard recent news that Novartis and Bristol Myers Squibb (BMS) have paused certain clinical trials of experimental CAR T-cell therapies…
Continue Reading
FDA Approves First Oral Treatment for Adults with Dermatomyositis
If you’ve been hearing cheers from TMA today, there’s a good reason. We are absolutely thrilled to share news that many patients, care partners, clinicians, and researchers have been working…
Continue Reading
New Hope on the Horizon
Promising Trial News from argenx and Abcuro The myositis community recently received encouraging news from two companies developing treatments for different forms of myositis. While much work remains before these…
Continue Reading
Inflammation May Affect Mood
Children and teens living with idiopathic inflammatory myopathies (IIM)—including juvenile dermatomyositis (JDM)—often face more than muscle weakness, fatigue, and skin symptoms. Many also struggle with mental health challenges, such as…
Continue Reading
Research Sheds Light on the Mental Health Journey in Myositis
Living with myositis is not only a physical challenge—it is deeply emotional. New research presented at the 2026 Global Conference on Myositis (GCOM) by TMA and in partnership with Keenova…
Continue Reading